8 rezultati
1. BACKGROUND In 2002, the Philippines changed its antimalarial drug policy to the combination treatment, CQ+ Sulphadoxine-pyrimethamine (SP) as 1st-line treatment and artemether-lumefantrine as 2nd-line treatment. The Department of Health (DOH) prescribed the use of artemether-lumefantrine (AL)
Objectives: The primary objective of the trial is to determine the optimum PMC delivery mechanism by comparing community- versus health facility-based strategies in order to inform policy.
Study Type: This is a single-centre, matched, cluster randomized, 5-arm, factorial design trial comparing the
3.1 STUDY DESIGN Children with uncomplicated malaria meeting the inclusion criteria will be enrolled (after their parent/caretaker has given informed consent), treated on site with the drugs under evaluation and followed-up for a period of 42 days. Drugs will be given under direct supervision,
Methodology Children of either gender, between 6 months (> 5kg) and 10 years of age, with acute uncomplicated P. falciparum infection, who fulfil all of the inclusion and have none of exclusion criteria will be enrolled in the study. They will be randomised to receive the three trial arms, i.e,
Background Plasmodium falciparum causes malaria and approximately 665 000 deaths each year. Previously chloroquine (CQ) and sulphadoxine-pyrimethamine were the principle drugs for the treatment of malaria. Due to widespread resistance to these drugs1, the World Health Organization recommends that P.
Study design and site An open randomized study was conducted to test the hypothesis that the risk of recurrent parasitaemia after 42 days is not inferior in the group receiving artesunate and amodiaquine (ASAQ) regimen compared to the group receiving artemether-lumefantrine (AL) regimen.
The
Study Title:
Efficacy and Safety of Quinine vs Artemether/Lumefantrine in uncomplicated malaria during pregnancy, Mbarara, Uganda (2006/2007).
Regulatory Status:
Investigational - Phase IV
Investigational Product and route:
- Quinine hydrochloride, oral route.
- Coartem® (Novartis Pharma AG, Basel,
Primary objective:
To assess the level of resistance to artemisinin derivatives in Western Cambodia.
Secondary objective:
To assess the level of resistance to other antimalarial drugs in Western Cambodia
1. Background; There are worrying signs from Western Cambodia that parasitological responses to